Home >> Cardiovascular & Haematological Disorders - Drug Targets, Volume 9, Number 2

May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?

Authors: Bocci, Velio; Travagli, Valter; Zanardi, Iacopo

Source: Cardiovascular & Haematological Disorders - Drug Targets, Volume 9, Number 2, June 2009 , pp. 78-85(8)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $62.88 plus tax (Refund Policy)

Abstract:

In an aging population vascular disorders well exemplified by the chronic limb ischemia, chronic heart failure, cerebral ischemia and age-related macular degeneration represent a serious medical and socio-economical problem. While there is always a not easily identifiable first pathogenic noxa, all of these diseases are characterized by ischemia, chronic inflammation and tissue degeneration. Orthodox medicine has provided several optimal drugs targeting various pathological situations but, even with their concomitant applications, it is not possible to reduce the chronic oxidative stress. Here it is proposed to associate the approach of ozonated autohemotherapy as a modifier of the biological response capable to block the pathological progress.

Keywords: Chronic limb ischemia; chronic heart failure; ictus; age-related macular degeneration; chronic oxidative stress; ozone therapy

Document Type: Research article

Publication date: 2009-06-01

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
Related content
Marked list

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page